Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The EU approval of the disease resistance activator, laminarin, has received its formal renewal as a “low-risk” active ingredient.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.